Similar Search Results

Ending Pay for PBM Performance : Consequences for Prescription Drug Prices, Utilization, and Government Spending

Mulligan, Casey B. - National Bureau of Economic Research - 2023

Proposed "delinking" legislation would prohibit Pharmacy Benefit Managers (PBMs) from being remunerated based on the rebates and discounts they negotiate for drug insurance plans serving Medicare beneficiaries. This policy would significantly change drug pricing and utilization and shift...

Persistent link: https://www.econbiz.de/10014372424

Cross-National Evidence on Generic Pharmaceuticals : Pharmacy vs. Physician-Driven Markets

Danzon, Patricia Munch - 2011

to payers and consumers of pharmaceuticals. Whether the potential savings are realized depends on the extent of generic …

Persistent link: https://www.econbiz.de/10012461428

Common Agent or Double Agent? Pharmacy Benefit Managers in the Prescription Drug Market

Conti, Rena M.; Frandsen, Brigham; Powell, Michael L.; … - National Bureau of Economic Research - 2021

pharmaceuticals bid for preferred slots on the PBM's formulary by offering rebates off of list price. We find that PBMs enhance …

Persistent link: https://www.econbiz.de/10012533415

Rebates in the Pharmaceutical Industry : Evidence from Medicines Sold in Retail Pharmacies in the U.S

Kakani, Pragya - 2020

Rising list prices are often used to illustrate the burden of prescription drug spending, but payers routinely negotiate rebates from manufacturers that generate differences between list and net prices. List prices are easily available and affect patient cost-sharing, but net prices are...

Persistent link: https://www.econbiz.de/10012482027

The Value of Pharmacy Benefit Management

Mulligan, Casey B. - National Bureau of Economic Research - 2022

In theory, equilibrium profits for drug patent holders would not involve significant restraints on production and patient utilization if the market had a mechanism for two-part pricing (Oi 1971) or quantity commitments (Murphy, Snyder, and Topel 2014). In fact, patent expiration has little...

Persistent link: https://www.econbiz.de/10013334448

Pharmacy Benefit Managers and Vertical Relationships in Drug Supply : State of Current Research

Brot-Goldberg, Zarek C.; Che, Catherine; Handel, Benjamin R. - National Bureau of Economic Research - 2022

Despite their importance to the supply of prescription drugs, there has been limited research on pharmacy benefit managers (PBMs) and their vertical relationships to insurers and drug manufacturers. This paper provides an overview of the current state of research on this topic, motivates why...

Persistent link: https://www.econbiz.de/10013191054

Towards an Efficient Mechanism for Prescription Drug Procurement

Fong, Kyna - 2009

This paper applies ideas from mechanism design to model procurement of prescription drugs. We present a mechanism for government-funded market-driven drug procurement that achieves very close to full static efficiency -- all members have access to all but at most a single drug -- without...

Persistent link: https://www.econbiz.de/10012463929

The Cost of US Pharmaceutical Price Reductions : A Financial Simulation Model of R&D Decisions

Abbott, Thomas A. - 2005

reduced-form model specifications. In the current paper we take a very different approach: a prospective micro-simulation …

Persistent link: https://www.econbiz.de/10012467571

Patient Responses to Incentives in Consumer-directed Health Plans : Evidence from Pharmaceuticals

Huckfeldt, Peter J. - 2015

use of pharmaceuticals for chronic diseases. We compare two large firms where nearly all employees were switched to CDHPs … to firms with conventional health insurance plans. In the first firm's CDHP, pharmaceuticals were subject to the … deductible, while in the second firm pharmaceuticals were exempt. Employees in the first firm shifted the timing of drug …

Persistent link: https://www.econbiz.de/10012457739

Active Choice, Implicit Defaults, and the Incentive to Choose

Beshears, John - 2019

Home-delivered prescriptions have no delivery charge and lower copayments than prescriptions picked up at a pharmacy. Nevertheless, when home delivery is offered on an opt-in basis, the take-up rate is only 6%. We study a program that makes active choice of either home delivery or pharmacy...

Persistent link: https://www.econbiz.de/10012479429